ketamine has been researched along with Multiple Sclerosis in 4 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The proposed study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of intravenous low-dose ketamine in patients with MS fatigue." | 9.69 | Low-dose ketamine infusion for the treatment of multiple sclerosis fatigue (INKLING-MS): Study protocol for a randomized, double-blind, active placebo-controlled phase II trial. ( Ghajarzadeh, M; Nourbakhsh, B; Roman, S; Vega, L, 2023) |
| "To determine the tolerability, safety, and efficacy of low-dose ketamine infusion for MS-related fatigue." | 9.41 | Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue. ( Balshi, A; Fitzgerald, KC; Kaplin, A; Maher, D; Morris, B; Nourbakhsh, B; Soroosh, A, 2021) |
| "The proposed study is a single-center, phase II, randomized, double-blind, parallel-group, active-placebo-controlled trial of intravenous low-dose ketamine in patients with MS fatigue." | 5.69 | Low-dose ketamine infusion for the treatment of multiple sclerosis fatigue (INKLING-MS): Study protocol for a randomized, double-blind, active placebo-controlled phase II trial. ( Ghajarzadeh, M; Nourbakhsh, B; Roman, S; Vega, L, 2023) |
| "To determine the tolerability, safety, and efficacy of low-dose ketamine infusion for MS-related fatigue." | 5.41 | Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue. ( Balshi, A; Fitzgerald, KC; Kaplin, A; Maher, D; Morris, B; Nourbakhsh, B; Soroosh, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, X | 1 |
| Chang, L | 1 |
| Tan, Y | 1 |
| Qu, Y | 1 |
| Shan, J | 1 |
| Hashimoto, K | 1 |
| Ghajarzadeh, M | 1 |
| Roman, S | 1 |
| Vega, L | 1 |
| Nourbakhsh, B | 2 |
| Fitzgerald, KC | 1 |
| Morris, B | 1 |
| Soroosh, A | 1 |
| Balshi, A | 1 |
| Maher, D | 1 |
| Kaplin, A | 1 |
| Losada de Azpiazu, FJ | 1 |
| Sánchez Del Mazo, T | 1 |
| Rodríguez Alvarez, E | 1 |
| Villar Mirabal, I | 1 |
| Fraga García, M | 1 |
| Pose Cambeiro, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ketamine and Multiple Sclerosis
| Article | Year |
|---|---|
Low-dose ketamine infusion for the treatment of multiple sclerosis fatigue (INKLING-MS): Study protocol for a randomized, double-blind, active placebo-controlled phase II trial.
Topics: Adult; Clinical Trials, Phase II as Topic; Double-Blind Method; Fatigue; Humans; Ketamine; Midazolam | 2023 |
Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis-related fatigue.
Topics: Double-Blind Method; Fatigue; Humans; Ketamine; Multiple Sclerosis; Pilot Projects; Treatment Outcom | 2021 |
2 other studies available for ketamine and Multiple Sclerosis
| Article | Year |
|---|---|
(R)-ketamine ameliorates the progression of experimental autoimmune encephalomyelitis in mice.
Topics: Animals; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; Humans; Ketamine; Mice | 2021 |
[Anesthesia in multiple sclerosis patients: a proso of a clinical case].
Topics: Adult; Anesthesia; Diazepam; Epinephrine; Humans; Ketamine; Male; Multiple Sclerosis; Urinary Bladde | 1982 |